Top Stories Thursday, December 22, 2016 Biotech enters every new year facing a wall of uncertainty. But with 2016’s wildcard Republican primary candidate becoming 2017’s POTUS, the list of outstanding questions confronting biotech this year is particularly long—and the implications of the answers could be significant. Thursday, December 22, 2016 At almost 1,000 pages, the 21st Century Cures Act is quite literally a weighty piece of legislation that will have far-reaching consequences for pharma in 2017 and beyond. Thursday, December 22, 2016 It is now six months since Britain voted to leave the European Union. In that time, a new government has set up two new departments, set out a tweaked economic strategy and fielded a near-constant stream of questions about Brexit. And yet biotech, like all other industries and the British public, is no closer to knowing what life will look like post-Brexit than it was on June 24. Thursday, December 22, 2016 2017 is promising to be a landmark year for synthetic biology as two technologies—CRISPR/Cas9 and CAR-T—head toward critical milestones. Thursday, December 22, 2016 This year will not go down as a classic for biotech IPOs; in fact, it’s been pretty dismal, with a report by Renaissance Capital out in the summer showing that almost all of the biotech IPOs that priced since the first quarter have broken issue, and were trading below their offer price. | | | Roche's bleeding drug emicizumab has hit its primary endpoint in a late-stage test. Release PharmaMar and Chugai have struck a license and commercialization pact for cancer med PM1183 in Japan. Statement Ionis has been given a $5 million milestone payment from partner Janssen for pushing on with a new program under the pair's GI collab. Release | |
|
Resources Presented By: Lenovo Get the stats you need to start down the path to a more secure infrastructure, today. Presented By: Lenovo What's the first step to a better patient experience? The patient experience starts well before the exam room or even reception - it begins as soon as your patients pull into the parking structure. Presented by: DocuSign DocuSign’s eSignature solutions modernize healthcare and life science organizations by eliminating paper and antiquated signature processes while meeting compliance requirements and reducing costs and errors. Presented by: DocuSign The patients who rely on your scientific leadership are expecting more. Presented by: DocuSign The U.S. Department of Justice has collected upwards of $17 billion in settlements from the healthcare industry since 2009, including more than $2 billion from a single life sciences company. Sponsored By: Salesforce Life sciences companies, like many industries today, face new challenges across the board. Read More. Presented By: ISR Reports Make essential outsourced bioprocessing decisions by staying informed of industry outsourcing practices and contract manufacturer usage patterns with ISR’s Bioprocessing Services and Technologies Market Trends and Outsourcing Dynamics report. Presented By: ISR Reports ISR’s Biosimilars in the US Oncology Market (2nd Edition) report provides data and insights from 101 US-based, board-certified oncologists/hematologist oncologists as to their expectations, fears, and aspirations for biosimilars in oncology. Presented By: ISR Reports Pinpoint the information oncologists find most valuable and the best sales channels for delivering specific types of data/information. Presented By: ISR Reports ISR’s Bioprocessing Market Trends and Outsourcing Dynamics: 2016-2021 report provides an overview of the current market dynamics for bioprocessing as well as an outlook on what the marketplace will look like in five years. Presented By: ISR Reports ISR’s CRO Quality Benchmarking – Phase II/III Service Providers (8th Edition) report provides a Consumer Reports-style analysis of Phase II/III CRO service quality from hundreds of users who rated 44 Phase II/III CROs across 26 critical dimensions of quality. Presented by: Patheon Can you avoid a risky trial-and-error approach to find the right path for your poorly soluble molecule by utilizing a CDMO? Download this complimentary Whitepaper to learn more! Sponsored by: Veeva Systems Gartner research on short- and long-term strategies for IDMP compliance. Drug Development Boot CampTM 2017 November 15-16, 2017 | Boston, MA FierceBiotech Executive Breakfast: Deciphering Immuno-Oncology, Trends in Deal-Making and R&D January 10, 2017 | San Francisco, CA CBI’s IISR 2017 Summit February 14-15, 2017 | Philadelphia, PA | 